X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2484) 2484
Publication (160) 160
Book Review (32) 32
Book Chapter (10) 10
Magazine Article (8) 8
Newsletter (8) 8
Conference Proceeding (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2101) 2101
male (1324) 1324
lorazepam (1193) 1193
female (1175) 1175
lorazepam - therapeutic use (1167) 1167
adult (1100) 1100
middle aged (733) 733
psychiatry (698) 698
index medicus (647) 647
pharmacology & pharmacy (618) 618
benzodiazepines (510) 510
aged (466) 466
lorazepam - administration & dosage (385) 385
double-blind method (382) 382
anti-anxiety agents - therapeutic use (379) 379
diazepam (372) 372
adolescent (356) 356
clinical neurology (356) 356
neurosciences (325) 325
lorazepam - adverse effects (292) 292
treatment outcome (291) 291
anticonvulsants - therapeutic use (256) 256
antipsychotic agents - therapeutic use (238) 238
drug therapy, combination (232) 232
lorazepam - pharmacology (223) 223
hypnotics and sedatives - therapeutic use (220) 220
benzodiazepines - therapeutic use (217) 217
midazolam (197) 197
animals (191) 191
dose-response relationship, drug (190) 190
time factors (180) 180
status epilepticus - drug therapy (169) 169
seizures (160) 160
status epilepticus (158) 158
schizophrenia (153) 153
child (152) 152
diazepam - therapeutic use (152) 152
double-blind (148) 148
benzodiazepine (144) 144
catatonia - drug therapy (144) 144
clinical trials as topic (139) 139
drugs (139) 139
psychiatric status rating scales (133) 133
haloperidol (132) 132
pharmacokinetics (132) 132
anti-anxiety agents - adverse effects (130) 130
psychomotor agitation - drug therapy (127) 127
young adult (126) 126
anxiety (125) 125
epilepsy (123) 123
catatonia (120) 120
pediatrics (120) 120
care and treatment (119) 119
management (118) 118
haloperidol - therapeutic use (117) 117
medicine, general & internal (117) 117
drug therapy (116) 116
children (115) 115
sedation (114) 114
prospective studies (111) 111
hypnotics and sedatives - administration & dosage (109) 109
anti-anxiety agents - pharmacology (108) 108
analysis (106) 106
alprazolam (105) 105
anxiety disorders - drug therapy (105) 105
drug administration schedule (104) 104
anxiety - drug therapy (103) 103
administration, oral (101) 101
efficacy (100) 100
acute disease (98) 98
electroencephalography (97) 97
midazolam - therapeutic use (96) 96
antipsychotic agents - adverse effects (92) 92
aged, 80 and over (91) 91
anti-anxiety agents - administration & dosage (91) 91
memory (91) 91
seizures - drug therapy (91) 91
injections, intravenous (90) 90
psychomotor performance - drug effects (89) 89
anticonvulsants - administration & dosage (88) 88
retrospective studies (88) 88
electroconvulsive therapy (87) 87
placebo (87) 87
rats (86) 86
dosage and administration (85) 85
lorazepam - analogs & derivatives (85) 85
emergency medicine (84) 84
benzodiazepines - adverse effects (83) 83
child, preschool (83) 83
neurology (83) 83
research (82) 82
antipsychotic agents - administration & dosage (80) 80
cross-over studies (80) 80
health aspects (80) 80
catatonia - diagnosis (79) 79
lorazepam - pharmacokinetics (79) 79
psychology (79) 79
diagnosis, differential (78) 78
olanzapine (78) 78
risk factors (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2378) 2378
French (39) 39
German (36) 36
Spanish (18) 18
Italian (12) 12
Russian (9) 9
Dutch (8) 8
Japanese (8) 8
Polish (2) 2
Portuguese (2) 2
Danish (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmacological Reviews, ISSN 0031-6997, 03/2011, Volume 63, Issue 1, pp. 243 - 267
GABA is the major inhibitory neurotransmitter in the central nervous system (CNS). The type A GABA receptor (GABA(A)R) system is the primary pharmacological... 
ADULT-RAT BRAIN | TEMPORAL-LOBE EPILEPSY | ANTAGONIST RO 15-1788 | CONVULSIVE STATUS EPILEPTICUS | DOSE INTRAVENOUS LORAZEPAM | MESSENGER-RNA EXPRESSION | GABA(A) RECEPTOR SUBUNITS | PHARMACOLOGY & PHARMACY | AMINOBUTYRIC ACID(A) RECEPTORS | GATED ION CHANNELS | HUMAN LIVER-MICROSOMES | Hypnotics and Sedatives - chemistry | Central Nervous System - metabolism | Anesthetics, Intravenous - therapeutic use | gamma-Aminobutyric Acid - metabolism | Humans | Anesthetics, Intravenous - chemistry | Hypnotics and Sedatives - therapeutic use | Receptors, GABA-A - chemistry | GABA-A Receptor Agonists - chemistry | Anti-Anxiety Agents - pharmacokinetics | Anesthetics, Intravenous - pharmacology | Drug Interactions | GABA-A Receptor Agonists - pharmacology | Anti-Anxiety Agents - chemistry | Neurons - metabolism | Anti-Anxiety Agents - therapeutic use | Neurons - drug effects | GABA-A Receptor Agonists - pharmacokinetics | GABA-A Receptor Agonists - therapeutic use | Benzodiazepines - pharmacology | Hypnotics and Sedatives - pharmacokinetics | Anti-Anxiety Agents - pharmacology | Benzodiazepines - pharmacokinetics | Animals | Neurons - enzymology | Receptors, GABA-A - genetics | Anesthetics, Intravenous - pharmacokinetics | Benzodiazepines - chemistry | Central Nervous System - drug effects | Hypnotics and Sedatives - pharmacology | Receptors, GABA-A - metabolism | Benzodiazepines - therapeutic use | Central Nervous System - enzymology
Journal Article
Journal of Emergency Medicine, ISSN 0736-4679, 2017, Volume 53, Issue 1, pp. 38 - 48
Abstract Background Intranasal (IN) medication delivery is a viable alternative to other routes of administration, including intravenous (IV) and intramuscular... 
Emergency | nasal | intranasal | medication | prehospital | emergency department | RECTAL DIAZEPAM | STATUS EPILEPTICUS | LACERATION REPAIR | RANDOMIZED CONTROLLED-TRIAL | PROCEDURAL SEDATION | POSTOPERATIVE PAIN MANAGEMENT | ACUTE SEIZURES | EMERGENCY MEDICINE | DOUBLE-BLIND | OPIOID OVERDOSE | INTRAVENOUS LORAZEPAM | Fentanyl - administration & dosage | Anesthetics, Dissociative - therapeutic use | Emergency Service, Hospital - trends | Narcotic Antagonists - administration & dosage | Fentanyl - therapeutic use | Humans | Hypnotics and Sedatives - administration & dosage | Haloperidol - administration & dosage | Midazolam - administration & dosage | Anticonvulsants - administration & dosage | Narcotics - therapeutic use | Antidotes - administration & dosage | Hypnotics and Sedatives - therapeutic use | Ketamine - administration & dosage | Lorazepam - therapeutic use | Administration, Intranasal - methods | Antipsychotic Agents - therapeutic use | Emergency Service, Hospital - organization & administration | Flumazenil - administration & dosage | Midazolam - therapeutic use | Ketamine - therapeutic use | Dexmedetomidine - administration & dosage | Dexmedetomidine - therapeutic use | Anesthetics, Dissociative - administration & dosage | Anticonvulsants - therapeutic use | Haloperidol - therapeutic use | Naloxone - therapeutic use | Lorazepam - administration & dosage | Antipsychotic Agents - administration & dosage | Flumazenil - therapeutic use | Hydromorphone - administration & dosage | Narcotics - administration & dosage | Narcotic Antagonists - therapeutic use | Hydromorphone - therapeutic use | Naloxone - administration & dosage | Antidotes - therapeutic use | Drugs | Usage | Emergency service | Hospitals | Emergency medicine
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2009, Issue 4, p. CD006379
Journal Article
Molecular Psychiatry, ISSN 1359-4184, 07/2006, Volume 11, Issue 7, pp. 680 - 684
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E-2 ( PGE(2)), have repeatedly been... 
COX-2 inhibition | Inflammation | Psychoneuroimmunology | Major depression | Immunity | SYSTEM | COX-2 | PSYCHIATRY | BIOCHEMISTRY & MOLECULAR BIOLOGY | psychoneuroimmunology | SCHIZOPHRENIA | SICKNESS BEHAVIOR | SYMPTOMS | immunity | NEUROSCIENCES | INFLAMMATORY MARKERS | INTERFERON-ALPHA | PROSTAGLANDINS | inflammation | ROFECOXIB | major depression | BRAIN | Anti-Anxiety Agents - administration & dosage | Dinoprostone - analysis | Pyrazoles - therapeutic use | Adrenergic Uptake Inhibitors | Dinoprostone - biosynthesis | Humans | Middle Aged | Depressive Disorder - drug therapy | Male | Patient Dropouts | Lorazepam - therapeutic use | Inflammation - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Female | Antidepressive Agents - pharmacology | Anti-Anxiety Agents - therapeutic use | Drug Therapy, Combination | Morpholines - therapeutic use | Pyrazoles - pharmacology | Severity of Illness Index | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Cyclooxygenase 2 Inhibitors - administration & dosage | Morpholines - administration & dosage | Lorazepam - administration & dosage | Celecoxib | Sulfonamides - pharmacology | Antidepressive Agents - therapeutic use | Pilot Projects | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Depressive Disorder - physiopathology | Serotonin - metabolism | Interleukin-6 - biosynthesis | Antidepressive Agents - administration & dosage | Psychological Tests | Sulfonamides - administration & dosage | Inflammation - physiopathology
Journal Article